Harrow Inc. (NASDAQ:HROW) shares are down during Tuesday’s premarket session as the company faces scrutiny following its recent financial results announcement.

The eye disease medicine maker, Harrow, reported fourth quarter earnings of 17 cents per share, missing the consensus estimate of 38 cents.

Sales jumped from $66.81 million to $89.09 million, beating the consensus of $88.45 million.

During the fourth quarter and full-year ended December 31, 2025, Harrow recorded $8.5 million in acquired in-process research and development expenses related to its acquisition of Melt Pharmaceuticals.

Management Commentary

“I also believe we are going to provide positive surprises this year (and next) with a few products in our portfolio that haven’t received much attention. With multiple growth drivers gaining traction and a larger commercial footprint coming online, I have increasing confidence in ...